Abstract. The loss of the CD16a, Fc receptor for IgG type III, (FcÁRIIIa) B73
Introduction
The CD16 molecule, Fc receptor for IgG type III (FcÁRIII), is a glycoprotein expressed in NK cells, subpopulation of non-classical ('proinflammatory') CD14 + CD16 ++ monocytes (FcÁRIIIa), and neutrophils (FcÁRIIIb) (1) (2) (3) . This receptor is engaged in antibody-dependent cellular cytotoxicity (ADCC) and plays a role in immunoregulation of proinflammatory response of leukocytes following binding of IgG (4) (5) (6) . Several clones of anti-CD16 monoclonal antibodies (mAbs) are available for routine enumeration of NK cells and in immunophenotyping of proinflamatory monocytes. The mAbs include B73.1/Leu11c, GRM1, and PEN1 clones recognizing epitopes located at the first extracellular Ig-like domain, and the mAbs of 3G8, CLBFcRgran1, MEM-154 and Leu11a clones, recognizing epitopes at the membrane-proximal Ig-like domain in which the IgG binding site has been described (7, 8) .
The gene coding FcÁRIIIa is very similar to a nearby gene coding FcÁRIIIb and both genes are located on chromosome 1 (9) . Several polymorphisms of FcÁRIIIa have been characterized and two of them, associated with changes of amino acids at position 48 and 158, have been linked with higher susceptibility to viral infections, especially with Herpesviridae, and various Fc fragments of IgG binding capacity, respectively. The polymorphism at position 48 is located at the first extracellular Ig-like domain of FcÁRIIIa and results in the expression of either leucine (L), arginine (R) or histidine (H), with gene frequencies in Caucasians of 86, 6 and 8%, respectively (10) . The latter polymorphism, at amino acid position 158, is located at the membrane-proximal domain and results in expression of the phenylalanine (F) or valine (V) (11) . It was observed that the FcÁRIIIa-158F polymorphism is linked to 48L isoform, while 158V with 48R or 48H (10, 12) .
The polymorphism occurring at position 158 of the CD16 protein chain has been reported to influence the binding of Fc fragments of IgG by the receptor and has been connected with a higher risk of the development of autoimmune diseases (10, 11) . The increased frequency of 158F/F isoform, which is a low IgG binding phenotype, was observed in patients with systemic lupus erythematosus (13) (14) (15) , whereas a high IgG binding 158V/V isoform has been correlated with the higher risk of rheumatoid arthritis (16, 17) . Moreover, studies on the association of certain FcÁRIIIa-158 isoforms with the efficiency of anti-CD20 mAbs therapy (18, 19) suggest that the presence of 158V/V or 158F/V phenotype predisposes to higher overall response to this therapy (18, 20, 21) . Eleven other described polymorphisms in the FcÁRIIIa gene (Entrez Gene database, SNP for gene ID: 2214) were not connected with any specific clinical manifestations.
Several studies (8, (22) (23) (24) reported that the substitution of L by R or H at amino acid position 48 in the FcÁRIIIa receptor predisposes to recurrent viral infections of respiratory tract, herpes virus infections and low cytotoxic activity of NK cells. These reports suggest that the NK cells of patients with FcÁRIIIa-48R or -48H did not react with anti-CD16 mAb of B73.1/Leu11c clone. Since the FcÁRIIIa-48R or -48H polymorphism was described to occur in a frequency of 14% in Caucasians (10), the rarity of reports of patients with NK cell defect (B73.1/Leu11c epitope loss) seems inexplicable, despite the common usage of the B73.1/Leu11c mAb in the immunophenotyping procedures of NK cells and monocyte subsets. Due to the predictable high frequency of the FcÁRIIIa-48 polymorphism, it is important to determine whether the FcÁRIIIa-48 polymorphism is indeed connected with the B73.1/Leu11c epitope loss. Recurrent viral infections, especially of the respiratory tract, are typical for patients with primary immunodeficiencies (25, 26) . What is more, the frequent occurrence of recurrent viral infections in patients with immunodeficiency diseases suggest that it is necessary to determine the frequency of the occurrence of the B73.1/Leu11c epitope loss in these patients. Moreover, the decreased activity of NK cells is correlated with the higher risk of cancer development (27) . Therefore, NK cell defect analysis appears to be important also in cases of patients with cancer. In this study we present the analysis of the occurrence of the B73.1/Leu11c epitope loss in patients with different primary immunodeficiency diseases and patients with gastrointestinal malignancies in comparison to age matched healthy control subjects. We also present genetic analysis of the entire coding region of FcÁRIIIa gene performed in the group of patients lacking B73.1/Leu11c epitope and control group of healthy individuals whose NK cells and monocytes were reactive with B73.1/Leu11c mAbs.
Materials and methods
Patients. The patient group included: 167 patients with primary immunodeficiency diseases and 91 patients with gastrointestinal malignancies (Table I) . As control, 88 healthy subjects were studied. Patients with immunodeficiency diseases were classified according to PAGID criteria (28) . Individuals whose cells were not reactive with anti-CD16a B73.1/Leu11c mAbs were chosen for genetic studies of the FcÁRIIIa gene. Their characteristics are presented in Table II . The genotyping of FcÁRIIIa gene was also performed in a group of 11 randomly chosen healthy control subjects with NK cells and monocytes that were reactive with anti-CD16a B73.1/Leu11c mAb. The Ethics Committee of the Jagiellonian Sequence analysis. DNA was extracted from whole peripheral blood samples using QIAmp DNA Mini Kit (Qiagen, Hilden, Germany). PCR was performed in a total volume of 20 μl, with 100 ng DNA, 200 μM of each dNTP, 0.5 U AmpliTaq Gold polymerase (Applied Biosystems, Foster City, CA, Table I . Characteristics of subjects included in the study. (20) . The thermocycling conditions were 10 min at 95˚C followed by 35 cycles at 95˚C for 15 sec, specific for each set of primers temperature of annealing (exon 1, 55˚C; 2, 55˚C; 3, 56˚C; 4, 54˚C; 5, 58˚C) for 30 sec, 72˚C for 30 sec, followed by final elongation for 10 min at 72˚C, then held in 4˚C. The PCR products were purified with a QIAquick PCR Purification Kit (Qiagen). Sequencing PCR was performed on the PCR products using exon-specific primer and Big Dye Terminator v3.1 Cycle Sequencing Kit (Applied Biosystems). The PCR assay was performed with 10 ng DNA, 8 μl Terminator Ready Reaction Mix, 3.2 pM of primer, described above, in a total volume of 20 μl and reaction was performed by 25 amplification cycles, 95˚C for 10 sec, 50˚C for 5 sec, 60˚C for 4 min, then held at 4˚C. PCR products were purified by ethanol/EDTA precipitation and dissolved in 25 μl of deionized formamide (Applied Biosystems), denatured at 95˚C for 3 min, and run on the Applied Biosystems 310 sequencing apparatus and analyzed with the Sequencing Analysis software (Applied Biosystems). For each exon the bidirectional sequence analysis was performed. The DNA sequencing results were aligned to the FcÁRIIIa gene sequence available in the Entrez Gene database (gene ID: 2214). In accordance to commonly used enumeration of FcÁRIIIa polymorphisms (10, 12, 20) the first nucleotide of the first codon for the first amino acid of the first extracellular domain was designated as nucleotide 1.
Results

Expression of FcÁRIIIa on monocytes and NK cells.
Peripheral blood lymphocytes and monocytes from patients with immunodeficiency diseases, cancer patients or healthy subjects were analyzed using two different clones of anti-CD16 mAbs, B73.1/Leu11c and 3G8 recognizing distinct epitopes of the FcÁRIIIa receptor (29) . NK cell population was determined as CD3 -/CD19 -cells in a lymphocytic gate, while monocytes were determined according to FSC and SSC parameters and CD14 positivity of the cells (Fig. 1) . The NK cells and monocytes of 11 pediatric patients with diagnosed primary immunodeficiency and one child with recurrent Table II . Clinical characteristics of patients with the CD16 B73.1/Leu11c epitope loss. 
infections were reactive only with the anti-CD16 3G8, but not with the B73.1/Leu11c mAbs, while the other analyzed patients and healthy subjects were reactive with both mAbs (Fig. 2) . These 12 patients (Table II) and 11 randomly chosen healthy subjects, whose B73.1/Leu11c mAb binding was not disturbed, were chosen for the genetic studies of the FcÁRIIIa gene polymorphisms.
Sequence analysis of FcÁRIIIa gene coding region.
Sequence analysis of the entire coding region of FcÁRIIIa gene (Table III) of the first, second and fifth exon did not reveal any nucleotide changes in the analyzed individuals in comparison to the reference sequence. However, within third and fourth exons, four different single nucleotide polymorphisms were detected, both in patients as well as the control group. Polymorphisms are summarized for each patient in Table III .
Within the third exon the FcÁRIIIa-48R or 48H isoforms, correlated with the B73.1/Leu11c epitope loss and higher susceptibility to viral infections, was not observed in any of the analyzed patients or healthy control subjects, due to the detected presence of FcÁRIIIa-48L/L isoform as only thymine (T) was detected at nucleotide position 230 (Fig. 3) . The nucleotide change of adenine (A) to guanine (G) within the third exon of FcÁRIIIa at nucleotide position 346, resulting in isoleucine (I) to V change at amino acid position 88, was detected in 2 patients (P2 and 11) and in 3 control subjects (C2, 8, 10 ) and all of them were FcÁRIIIa-88I/V heterozygotes.
Within the fourth exon of the FcÁRIIIa gene three polymorphisms were detected, at amino acid positions 129, 137 and 158. The nucleotide change of G to A at position 440 resulting in amino acid change of glycine (G) to aspartic acid (D) at position 129 was detected in patient 11 who was FcÁRIIIa-129D/D homozygote. Patients 4, 11 and 12 had FcÁRIIIa-137H/H variation due to T to cytosine (C) substitution at nucleotide position 472 and tyrosine (Y) to H change. In the control subjects, none had the FcÁRIIIa-129 or -137 polymorphism detected. The FcÁRIIIa-158 isoform was detected in 11 out of 12 analyzed patients and 5 out of 11 control subjects, since single nucleotide change of T to G at position 526 was confirmed, resulting in FcÁRIIIa-158V/V isoform. However, FcÁRIIIa-158 isoform was indeterminable in 1 patient (P10) and 6 control subjects (C5-8, 10 and 11). Those individuals had both T and G nucleotide detected at nucleotide position 526. The FcÁRIIIa-158 polymorphism was not confirmed in 7 analyzed subjects since two peaks of the same height on the electropherogram were detected at nucleotide position 526, one for T and one for G. It was not possible to establish whether this is due to the heterozygotic isoform of the FcÁRIIIa gene (526-T/G) and FcÁRIIIb isoform 526-G/T, or due to homozygotic isoforms of both genes, 526-T/T and 526-G/G, respectively. That is why, in case of these subjects, the amino acid position 158 polymorphism in the FcÁRIIIa receptor was marked as indeterminable.
Seven other FcÁRIIIa heterozygotic isoforms were noted in the third and fourth exons (at nucleotide positions 107, 114, 194, 274, 440, 472 and 498). In the fourth exon in all patients and control subjects C/T heterozygotic isoform at nucleotide position 498 (amino acid position 148) was detected. However, the C to T change of nucleotide position 498 did not change the amino acid position 148, so the FcÁRIIIa-148D/D phenotype was predicted in all analyzed individuals. Twenty Table III . Summary of detected polymorphisms and heterozygotic isoforms with predicted amino acids in the FcÁRIIIa gene. 
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Discussion
There are several reports describing children with low cytotoxic activity of NK cells and similar clinical characteristics, recurrent infections, mostly with Herpesviridae (8, (22) (23) (24) . These reports indicate that higher susceptibility to viral infection correlates with the NK cell defects that manifest as a loss of the CD16 B73.1/Leu11c epitope. The epitope loss was described to be caused by the change of the amino acid position 48 from L to R or H. However, the more recent reports described the amino acid position 48 to be polymorphic also in the healthy individuals, since R or H expression occurs in Caucasians with the frequency of ~14% (10) . That is why, the common usage of the anti-CD16 B73.1/Leu11c mAbs in routine immunodiagnostics should provide data on many more patients with NK cell defect. Therefore, it seems questionable that this rarely occurring defect is connected with the frequent polymorphism. Furthermore, the rarity of the studies reporting the subjects with recurrent viral infections and the FcÁRIIIa-48R/H polymorphism seems intriguing. Due to the higher frequency of viral infections in patients with primary immunodeficiency diseases and the connection of NK cell activity with cancer development, in this study we present the analysis of the frequency of CD16 B73.1/Leu11c epitope loss on NK cells and monocytes in a large group of patients with primary immunodeficiencies and patients with gastrointestinal malignancies.
From an entire group of analyzed individuals, the B73.1/ Leu11c epitope loss was detected only in 12 children, including 11 children with primary immunodeficiency diseases and one child with recurrent respiratory tract infections, but was not detected in patients with gastrointestinal malignancies and healthy subjects. According to the allele frequency provided by de Haas et al (10) in our group of 346 individuals studied, 14% subjects should exhibit the loss of B73.1/Leu11c epitope. However, the epitope loss was detected only in 12 subjects (3.5%). The sequence of the CD16 coding FcÁRIIIa gene of the patients with the epitope loss was also analyzed in comparison to healthy control subjects. The sequence analysis of the FcÁRIIIa gene revealed that in all patients and healthy subjects, L was present at amino acid position 48. These results indicate that the FcÁRIIIa-48 polymorphism has no linkage with the CD16 B73.1/Leu11c mAbs binding capacity in the studied patients. Moreover, analyzing the clinical characteristics of analyzed patients, the correlation of the FcÁRIIIa-48R/H polymorphism with frequent herpes virus infections was not clearly associated. Other studies (8, (22) (23) (24) postulated the linkage between the loss of B73.1/Leu11c epitope, the presence of FcÁRIIIa-48 R or H isoforms and recurrent herpes viruses infections in one subject or siblings while in the present study, the group of 12 unrelated patients with the CD16 epitope loss was genotyped. However, though the group of analyzed patients did suffer from recurrent infections, there has been only one patient with recurrent Herpes simplex infections. Nevertheless, the cytotoxic activity of NK cells of the patients has not been analyzed and that is why it cannot be excluded that the activity of NK cells in patients with the epitope loss was diminished.
The sequence analysis of the entire FcÁRIIIa coding region did not reveal any other changes in the nucleotide sequence that could be responsible for the B73.1/Leu11c epitope loss. Moreover, four other polymorphisms were detected in patients and control subjects, including the changes of amino acids 88, 129, 137 and 158 (Table III) . The detected FcÁRIIIa-158V/V isoform was more frequent (69.6%) than described previously in Caucasians (20.5%) (10), yet it could be due to the relatively small group of genotyped subjects. Furthermore, in contrast to other findings that linked the FcÁRIIIa-158F polymorphism to 48L isoform and 158V with 48R or 48H (10, 12) , no linkage of FcÁRIIIa-48 and -158 genotypes was detected, as all subjects with FcÁRIIIa-158V/V were also FcÁRIIIa-48L/L. In seven subjects (P11 and C5-8, 10-11) the FcÁRIIIa-158 polymorphism was not identified due to the heterozygotic T/G isoform detected at 526 nucleotide. However, it can be assumed to be a result of the presence of two different nucleotides at the equivalent position in FcÁRIIIa and FcÁRIIIb genes. The analysis of FcÁRIIIa and FcÁRIIIb gene sequence (Entrez Gene database, gene ID: 2215) and possible binding of primers used in this study to the FcÁRIIIb gene indicate that in the case of nucleotide positions a precise identification of polymorphism was not performed. Both genes are highly similar and in the coding region differ only in some nucleotides. The nucleotide differences occur at the corresponding positions in both genes and at those positions a nucleotide in one gene could be substituted by another that is most frequently present at the same position in the second gene. That is why, in case of these subjects, the 158 amino acid polymorphism in the FcÁRIIIa receptor was marked as indeterminable. The same situation occurred with seven other FcÁRIIIa polymorphisms at nucleotides 107, 114, 194, 274, 440, 472, 498, and amino acid positions 18, 20, 47, 64, 129, 137, 148, respectively (Fig. 4) . These observations indicate that the method of DNA sequencing under the specific conditions applied in this study and other studies (8, 10, 12, 20) of the FcÁRIIIa gene could give ambiguous results not allowing complete determination of the nucleotide and amino acid at every polymorphic site of the FcÁRIIIa receptor.
In summary, our study suggests that the CD16 B73.1/ Leu11c epitope loss may be preferentially associated with the primary immunodeficiency diseases, but not with the occurrence of gastrointestinal malignancies. What is more, the epitope loss seems not to be associated with recurrent herpes viruses infections. Since the anti-CD16 B73.1/ Leu11c mAb is commonly used in routine immunodiagnostic procedures, the disturbed binding of the mAbs may contribute to low number of NK cells determined and may not enable to detect any of CD14 + CD16 ++ monocytes. Therefore, it is advisable to apply additional staining with different clones of the anti-CD16 mAbs in patients with the suspected B73.1/ Leu11c epitope loss. The cause of the epitope loss on NK cells and monocytes remains unsolved after sequence analysis of the entire coding region of FcÁRIIIa gene. However, the results of our study clearly indicate that this defect does not result from the change of the FcÁRIIIa genotype. This conclusion may explain the NK cell defects and why the B73.1/Leu11c epitope loss does not occur as frequent as the FcÁRIIIa-48R/H polymorphism. Nevertheless, we can only suspect, that the changes of the spatial structure of the receptor in the selected group of patients is responsible for a lack of binding of B73.1/Leu11c mAb. This change of the structure of the CD16a protein could result from different pattern of glycosylation of the receptor. However, further studies are required to solve this issue.
In summary, this study, based on analysis of the large group of individuals, revealed that disturbed binding of B73.1/Leu11c mAb may be associated with primary immunodeficiency diseases, but not with the FcÁRIIIa-48 polymorphism.
